IL 13 promoter (-1055) polymorphisms associated with chronic obstructive pulmonary disease in taiwanese

Experimental Lung Research

Volumn 35, Issue 10, 2009, Pages 807-816

  Liu, Shih Feng ^a   Chen, Yung Che ^a   Wang, Chin Chou ^a   Fang, Wen Feng ^a   Chin, Chien Hung ^a   Su, Mao Chang ^a   Lin, Meng Chih ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Chronic obstructive pulmonary disease; Interlukin 13; Single nucleotide polymorphism

Indexed keywords

DNA; INTERLEUKIN 13; PRIMER DNA;

AGED; ALLELE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOMICS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; BLOOD; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

AGED; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN-13; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TAIWAN;

EID: 72049127274     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902140902893644     Document Type: Article

References (26)

1. Lander ES, Schork NJ: Genetic dissection of complex traits. Science 1994;265:2037-2048.
2. Joos L, Pare PD, Sandford AJ: Genetic risk factors of chronic obstructive pulmonary disease. Swiss Med Wkly. 2002; 132: 27-37. (Pubitemid 34266546)
3. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, et al.: Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med. 1995;333:894-900.
4. Doull IJ, Lawrence S, Watson M, Begishvili T, Beasley RW, et al.: Allelic association of gene markers on chromosome 5q and 11q with atopy and bronchial hyperresponsiveness. Am J Respir Crit Care Med. 1996;153:1280-1284. (Pubitemid 26112591)
5. A genome-wide search for asthma susceptibility loci in ethnically diverse populations: The Collaborative Study on the Genetics of Asthma (CSGA). Nat Genet. 1997;15:389-392.
6. Whittaker L, Niu N, Temann UA, Stoddard A, Flavell RA, et al.: Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol. 2002;27:593-602.
7. Miotto D, Ruggieri MP, Boschetto P, Cavallesco G, Papi A, et al.: Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. Eur Respir J. 2003;22:602-608.
8. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, et al.: Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106:1081-1093.
9. Boutten A, Bonay M, Laribe S, Leseche G, Castier Y, et al.: Decreased expression of interleukin 13 in human lung emphysema. Thorax. 2004;59:850-854.
10. Van Der Pouw Kraan TC, Kucukaycan M, Bakker AM, Baggen JM, Van Der Zee JS, et al.: Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun. 2002;3:436-439. (Pubitemid 41656545)
11. Meyers DA, Larj MJ, Lange L. Genetics of asthma and COPD. Similar results for different phenotypes. Chest 2004;126(Suppl):105S-110S, 159S-161S.
12. Ohar JA, Bleecker ER, Howard TD. IL-13 polymorphism: predisposition towardsCOPDand asbestosinduced diseases [abstract]. Eur Respir J. 2001;18:P3588.
13. Hegab AE, Sakamoto T, Saitoh W, Massoud HH, Massoud HM, et al.: Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest. 2004;126:1832-1839.
14. Sadeghnejad A, Meyers DA, Bottai M, et al.: L13 promoter polymorphism 1112C/T modulates the adverse effect of tobacco smoking on lung function. Am J Respir Crit Care Med. 2007;176:748-752.
15. Cameron L, Webster RB, Strempel JM, et al.: Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C.T, a polymorphism associated with allergic inflammation. J Immunol. 2006;177:8633-8642.
16. Van Der Pouw Kraan TC, van Veen A, Boeije LC, et al.: An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun. 1999;1:61-65.
17. Lee JS, Rosengart MR, Kondragunta V, et al.: Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study. Respir Res. 2007;8:64.
18. Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425-456.
19. Ke B, Shen XD, Zhai Y, Gao F, Busuttil RW, et al.: Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther. 2002;13:1845-1857.
20. Kasahara Y, Tuder RM, Cool CD, et al.: Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737-744.
21. Segura-Valdez L, Pardo A, Gaxiola M, et al.: Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000;17:684-694.
22. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-280.
23. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary diseasemorbidity. Copenhagen City Heart Study Group.AmJ Respir Crit Care Med. 1997;153:1530-1535.
24. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8:1333-1338.
25. Cohn L, Homer RJ, MacLeod H, et al.: Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils. J Immunol. 1999;162:6178-6183.
26. McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN. A distinct role for interleukin-13 in Th2-cellmediated immune responses. Curr Biol. 1998;8:339-342.